These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37247633)

  • 1. Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?
    Yilmaz N; Gulsen Coban P; Yilmaz S; Inal HA; Timur H; Haltas H
    Gynecol Endocrinol; 2023 Dec; 39(1):2217295. PubMed ID: 37247633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.
    Ateş Ç; Dilbaz B; Ergani SY; Atabay F
    Rev Assoc Med Bras (1992); 2023; 69(11):e20230789. PubMed ID: 37909622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
    Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
    Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S
    Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N
    J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
    Kasap E; Turan GA; Eskicioğlu F; Cengiz H; Gur EB; Sivrikoz ON; Genc M; Yılmaz O
    Gynecol Endocrinol; 2016 Aug; 32(8):634-640. PubMed ID: 26939766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
    Engin-Ustun Y; Yılmaz S; Timur H; Ustun Y; Moraloglu O; Deveer R; Yılmaz N
    Gynecol Endocrinol; 2013 Sep; 29(9):851-4. PubMed ID: 23862585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model.
    Bakırcı Ş; Sağsöz N; Devrim T; Şahin Y; Bulanık M; Gözüyukarı H
    Gynecol Endocrinol; 2022 Dec; 38(12):1093-1096. PubMed ID: 36579847
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    Tang H; Mourad S; Zhai SD; Hart RJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
    Gaafar S; El-Gezary D; El Maghraby HA
    Reprod Biol; 2019 Jun; 19(2):145-148. PubMed ID: 31133458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
    Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose cabergoline in management of ovarian hyperstimulation syndrome.
    Ata B; Seyhan A; Orhaner S; Urman B
    Fertil Steril; 2009 Sep; 92(3):1168.e1-1168.e4. PubMed ID: 19539908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
    Carizza C; Abdelmassih V; Abdelmassih S; Ravizzini P; Salgueiro L; Salgueiro PT; Jine LT; Nagy P; Abdelmassih R
    Reprod Biomed Online; 2008 Dec; 17(6):751-5. PubMed ID: 19079957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
    Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
    Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
    Esinler I; Bozdag G; Karakocsokmensuer L
    Arch Gynecol Obstet; 2013 Nov; 288(5):1159-63. PubMed ID: 23677417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.